Higher Levels of C-Reactive Protein and Ferritin in Patients with Overweight and Obesity and SARS-CoV-2-Related Pneumonia

Bettini, Silvia; Bucca, Giovanni; Sensi, Caterina; Prà, Chiara Dal; Fabris, Roberto; Vettor, Roberto; Busetto, Luca

doi:10.1159/000517851

Cited by 8 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, inflammation is exacerbated more by hyperlipidemia and obesity, particularly in COVID-19 patients [ 28 ]. Non-survivors displayed elevated serum C-reactive protein, ferritin, and IL-6 levels upon hospital admission [ 29 , 30 ]. The intravenous administration of CIGB-258 (1 or 2 mg for every 12 h) showed the therapeutic potential to treat hyperinflammation of patients with COVID-19 with a remarkable decrease in cytokine levels present in “cytokine storm”, such as IL-6 and TNF-α [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I

Cho

Nam²,

Kim³

et al. 2023

IJMS

View full text Add to dashboard Cite

Inflammation and atherosclerosis are intimately associated via the production of dysfunctional high-density lipoproteins (HDL) and modification of apolipoprotein (apo) A-I. A putative interaction between CIGB-258 and apoA-I was investigated to provide mechanistic insight into the protection of HDL. The protective activity of CIGB-258 was tested in the CML-mediated glycation of apoA-I. The in vivo anti-inflammatory efficacy was compared in paralyzed hyperlipidemic zebrafish and its embryo in the presence of CML. Treatment of CML induced greater glycation extent of HDL/apoA-I and proteolytic degradation of apoA-I. In the presence of CML, however, co-treatment of CIGB-258 inhibited the glycation of apoA-I and protected the degradation of apoA-I, exerting enhanced ferric ion reduction ability. Microinjection of CML (500 ng) into zebrafish embryos resulted in acute death with the lowest survivability with severe developmental defects with interleukin (IL)-6 production. Conversely, a co-injection of CIGB-258 or Tocilizumab produced the highest survivability with a normal development speed and morphology. In hyperlipidemic zebrafish, intraperitoneal injection of CML (500 μg) caused the complete loss of swimming ability and severe acute death with only 13% survivability 3 h post-injection. A co-injection of the CIGB-258 resulted in a 2.2-fold faster recovery of swimming ability than CML alone, with higher survivability of approximately 57%. These results suggest that CIGB-258 protected hyperlipidemic zebrafish from the acute neurotoxicity of CML. Histological analysis showed that the CIGB-258 group had 37% lower infiltration of neutrophils in hepatic tissue and 70% lower fatty liver changes than those of the CML-alone group. The CIGB-258 group exhibited the smallest IL-6 expression in the liver and the lowest blood triglyceride level. CIGB-258 displayed potent anti-inflammatory activity in hyperlipidemic zebrafish by inhibiting apoA-I glycation, promoting rapid recovery from the paralysis of CML toxicity and suppression of IL-6, and lowering fatty liver changes.

show abstract

Section: Introductionmentioning

confidence: 99%

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I

Cho

Nam²,

Kim³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…This could be one of the factors explaining the worse severity and outcome seen in such a population. Similarly, a retrospective study showed that maximal CRP and ferritin levels during hospitalization were higher in obese than normal-weight COVID-19 patients [ 46 ]. Other markers of severity, including D-dimer, LDH, CRP, and ESR, were higher in obese patients in our study but were statistically insignificant.…”

Section: Discussionmentioning

confidence: 99%

The impact of obesity on hospitalized patients with COVID-19 infection in the Eastern Province of Saudi Arabia

et al. 2022

View full text Add to dashboard Cite

This study aimed to assess the association of obesity with the severity and outcome of COVID-19 infection. A retrospective observational study was performed from March to September 2020 in Saudi Arabia. Baseline and laboratory data were collected from the inpatient health record system. The cohort was divided into three groups based on body mass index. Following this, the severity and outcome of COVID-19 disease were analyzed between the three groups. Of the 502 COVID-19 cases included, 244 (48.5%) were obese. Obesity was significantly associated with severe (53.5%) or critical (28%) COVID-19 infection (P<0.001) and a higher need for ICU admission (35.8%, P=0.034). Multivariate analysis showed that overweight/obesity was an independent risk factor of severe (P<0.001) as well as critical COVID-19 infection (P=0.026, respectively) and a predictor of a higher risk of ICU admission (P=0.012). Class I obesity was associated with severe-critical COVID-19 disease (33.6%, P=0.042) compared to other obesity classes. Obesity is an independent risk factor for severe-critical COVID-19 infection and a higher risk of ICU admission. Clinicians should give special attention to such populations and prioritize vaccination programs to improve outcomes.

show abstract

“…Moreover, severe CoVID-19 has been associated with lower expression of IFN-γ by CD4 + , an antiviral protein [ 97 ]. It was demonstrated that patients with obesity and overweight presented higher levels of CRP and ferritin than patients with normal weight, in a CoVID-19 medical ward, whereas IL-6 levels were higher in all the subjects [ 98 ].…”

Section: Obesity Covid-19 and Low-grade Inflammation: Molecular Insightsmentioning

confidence: 99%

Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood

Muscogiuri¹,

Bettini

Boschetti

et al. 2022

Int J Obes

Self Cite

View full text Add to dashboard Cite

The new 2019 coronavirus 19 disease (CoVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious threat to health systems. As a global health problem, this pandemic poses a huge threat to people and is responsible for significant morbidity and mortality worldwide. On the other hand, obesity has also reached epidemic proportions and poses another challenge to the healthcare system. There is increasing evidence of a strong association between obesity and CoVID-19 disease, but the mechanisms underlying the link between the two remain unclear and the role of obesity also remains to be elucidated. In particular obesity-related low-grade inflammation has been hypothesized as the Achille’s heel that could predispose subjects with obesity to a more severe CoVID-19 compared to subjects with normal weight. Hence, we summarized recent evidence on the role of low-grade inflammation in clinical aspects of CoVID-19 in subjects with obesity in both childhood and adulthood. Further, we provide molecular insights to explain this link.

show abstract

Higher Levels of C-Reactive Protein and Ferritin in Patients with Overweight and Obesity and SARS-CoV-2-Related Pneumonia

Cited by 8 publications

References 13 publications

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I

CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I

The impact of obesity on hospitalized patients with COVID-19 infection in the Eastern Province of Saudi Arabia

Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood

Contact Info

Product

Resources

About